Cisplatin Promotes the Efficacy of Immune Checkpoint Inhibitor Therapy by Inducing Ferroptosis and Activating Neutrophils
The combination of immunotherapy with platinum-based chemotherapy has become the first-line treatment for patients with advanced non-small cell lung cancer (NSCLC) with negative driver gene mutations. However, finding an ideal chemotherapeutic regimen for immunotherapy and exploring the underlying m...
Saved in:
Main Authors: | Ziwei Zhou (Author), Yiming Zhao (Author), Si Chen (Author), Guohui Cui (Author), Wenkui Fu (Author), Shouying Li (Author), Xiaorong Lin (Author), Hai Hu (Author) |
---|---|
Format: | Book |
Published: |
Frontiers Media S.A.,
2022-06-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Application of immune checkpoint inhibitors for resectable gastric/gastroesophageal cancer
by: Feizhi Lin, et al.
Published: (2024) -
Biomarkers Associated with Immune Checkpoint, N6-Methyladenosine, and Ferroptosis in Patients with Restenosis
by: Tong X, et al.
Published: (2023) -
Neutrophil-related genes predict prognosis and response to immune checkpoint inhibitors in bladder cancer
by: Rui Yang, et al.
Published: (2022) -
Adverse Effects and Toxicity of Immune Checkpoint Inhibitors For Patients With Urothelial Carcinoma
by: Di Wang, et al.
Published: (2021) -
Predictive biomarkers for cancer immunotherapy with immune checkpoint inhibitors
by: Rilan Bai, et al.
Published: (2020)